A Randomized, Open-Label, 2 x 2 Crossover Phase 1 Study to Evaluate the Food Effect on the Pharmacokinetics (PK) and safety of Single Oral Dose of Azilsartan (TAK-536) Pediatric Formulation (10 mg) in Healthy Adult Male Subjects

Trial Profile

A Randomized, Open-Label, 2 x 2 Crossover Phase 1 Study to Evaluate the Food Effect on the Pharmacokinetics (PK) and safety of Single Oral Dose of Azilsartan (TAK-536) Pediatric Formulation (10 mg) in Healthy Adult Male Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Feb 2018

At a glance

  • Drugs Azilsartan (Primary)
  • Indications Essential hypertension
  • Focus Pharmacokinetics
  • Sponsors Takeda Pharma
  • Most Recent Events

    • 16 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 09 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top